Sentiment Scan — 2026-04-29

Date: 2026-04-29 | Analyst: intel-sentiment agent | Tickers: 37 (20 main + 17 rotating)

Key macro context: FOMC Day 2 (Powell's last statement), GOOGL+MSFT+AMZN earnings today post-close, AAPL+AXTI+NVCR+NOVT earnings tomorrow, sulfuric acid ban T-2, Hormuz Day 16 Brent $111+, POET -47% (SiPh Day 19 contagion test) [VERIFIED -- Macro context confirmed. Note: sulfuric acid ban is T-1 (May 1 effective), not T-2. Brent is $114.64 per TradingEconomics, not "$111+". Main report corrects these figures.]

Phase 0: Triage Results

Triage Summary: 29 Catalyst / 4 Noise / 4 Quiet

Phase 1-5: Catalyst Tickers — Full Analysis

GOOGL — Alphabet | Catalyst

Price: $349.78 | 52w range: $147.84–$353.18 | Extended-price rule applies (price within 1% of 52w high)

Narrative: Earnings catalyst + structural AI re-rate in progress. Cloud margin expected 27% (900bps YoY). $40B Anthropic investment signal. Price at 52w high with earnings catalyst = Accelerating (structural re-rate rule).

Velocity Score: +7 (analyst upgrades, Anthropic deal, AI cloud margin expansion expectations) Hype Score: 8/10 (earnings-driven, quantifiable) Narrative: Accelerating | Exhaustion signals: 1/5 (all-time high before earnings) Sentiment Gap: Price at 52w high — market is pricing in a beat; miss = -8% risk Catalyst Timeline: Earnings tonight (binary); Q2 AI cloud margins (gradient gradient positive) Verdict: Accelerating — Beat + cloud margin commentary would confirm structural re-rate. Miss risk is real at 52w high.

MSFT — Microsoft | Catalyst

Price: $429.25 | 52w range: $356.28–$555.45 | Below 52w high (23% gap)

Narrative: Earnings today. OpenAI partnership restructure — MSFT drops exclusive right to sell OpenAI models (April 27), but also stops sharing revenue. Structurally changes MSFT's AI moat perception. Azure expected 40%+ growth. Stock 23% below 52w high — room to recover if Azure beats.

Velocity Score: +5 (earnings catalyst, Azure expectations, OpenAI restructure mixed) Hype Score: 7/10 (Azure quantifiable; OpenAI restructure is complicated) Narrative: Stabilizing-to-Accelerating | Exhaustion signals: 0/5 Sentiment Gap: 23% below 52w high; if Azure beats with strong commentary, meaningful repricing gap Verdict: Watch — Azure beat + margin improvement = Accelerating. OpenAI restructure is double-edged (less lock-in risk but less exclusivity moat).

AMZN — Amazon | Catalyst

Price: $259.70 | 52w range: $178.85–$264.50 | Near 52w high (within 2%)

Narrative: Earnings today post-close. AWS AI ARR >$15B. Meta Graviton partnership. $200B 2026 capex. 92.2% Polymarket beat probability. Extended-price rule: near 52w high + fresh earnings/AI catalyst = Accelerating.

Velocity Score: +8 (65 buy ratings, zero sells, Polymarket 92%, AI partnerships) Hype Score: 8/10 (quantifiable AWS growth, confirmed partnerships) Narrative: Accelerating | Exhaustion signals: 2/5 (near all-time high, consensus fully bullish) Sentiment Gap: Price near highs; if AWS beats and capex commentary is positive, gap is small but narrative acceleration is the story Verdict: Accelerating — AWS beat confirmation is the catalyst. Any guide-down or capex-cut signal = deceleration.

NVDA — Nvidia | Catalyst

Price: $213.17 | 52w high: $216.83 | Within 2% of 52w high — extended-price rule

Narrative: New 52w high yesterday ($216.83). DBS raised PT to $250 (from $220). BofA reiterates $300 Buy. JPMorgan caution on "limits." GOOGL/MSFT/AMZN earnings tonight = proxy AI capex confirming events for NVDA. Extended-price + catalyst stack = Accelerating.

Velocity Score: +8 (multiple analyst upgrades, AI spending confirmation pending, near ATH) Hype Score: 9/10 (structural AI demand, quantifiable, track record impeccable) Narrative: Accelerating | Exhaustion signals: 2/5 (near ATH, consensus crowded) Catalyst Timeline: GOOGL/MSFT/AMZN earnings tonight (proxy catalyst); own earnings ~May Verdict: Accelerating — if tonight's hyperscaler earnings confirm capex continuation, NVDA trades through $216.83. The $31B footnote (export restriction headwind) is the primary bear case.

AAPL — Apple | Catalyst

Price: $270.71 | 52w high: $288.62 | Within 6% of 52w high

Narrative: Earnings tomorrow April 30. UBS PT $280→$287. CEO transition Cook→Ternus is the qualitative story. iPhone supply chain strength, 20% YoY expected. Extended-price + upcoming earnings = Accelerating.

Velocity Score: +6 (UBS upgrade, 56 Buy ratings, CEO transition narrative) Hype Score: 7/10 (quantifiable iPhone rev, services growth) Narrative: Accelerating | Exhaustion signals: 1/5 (near highs) Catalyst Timeline: Earnings tomorrow (binary); Q3 CEO transition commentary Verdict: Accelerating into earnings. Key risk: tariff impact on China manufacturing cost disclosure.

HIMS — Hims & Hers | Catalyst

Price: $27.91 | 52w range: $13.74–$70.43 | Far below 52w high (60% below)

Narrative: MAJOR inflection. JPMorgan Overweight initiation $35 PT (April 24) — analyst PT upgrade. Novo Nordisk Wegovy partnership operational (FDA-approved GLP-1s live on platform). Menopause/perimenopause care launch (new TAM). Amazon GLP-1 headwind creating 5% pullback. RFK Jr. peptide policy = future optionality. Lawsuit overhang resolved → strategic partnership. This is the classic Inflection signal — lawsuit became partnership, legal risk became market validation.

Catalyst stack: JPMorgan initiation + Novo partnership + menopause TAM expansion + peptide optionality = 4 concurrent catalysts

Velocity Score: +9 Hype Score: 7/10 (partnership is real, revenue impact being quantified; Amazon risk is real) Narrative: Inflection → trending Accelerating | Exhaustion signals: 0/5 Sentiment Gap: 60% below 52w high; $35 JPM PT vs $27.91 = +25% upside to initial target Public vs Expert: Mainstream focusing on Amazon headwind (bearish); experts see Novo partnership as thesis-changing (bullish divergence) Verdict: Asymmetric — narrative inflection clearly underway. Amazon GLP-1 entry is the near-term headwind to monitor; peptide legalization timeline (July PCAC meeting) is the next catalyst.

IREN — Iris Energy | Catalyst

Price: $44.44 | 52w range: $5.72–$76.87 | 42% below 52w high

Narrative: MSCI index inclusion (April 23) = index addition catalyst override. Microsoft AI deal. 50,000 B300 GPUs purchased. Sweetwater 1 (1.4 GW) launching April. $3.7B+ ARR target end-2026.

Catalyst stack: MSCI inclusion + Microsoft deal + B300 GPU purchase + facility launch = 4 catalysts Velocity Score: +7 Hype Score: 6/10 (Microsoft deal confirmed, MSCI real, revenue visibility moderate — execution risk on $3.7B ARR from current levels) Narrative: Accelerating | Exhaustion signals: 0/5 Sentiment Gap: 42% below 52w high; MSCI inclusion brings passive inflows; meaningful upside if AI transition executes Verdict: Accelerating — MSCI inclusion is structural inflow catalyst. GPU fleet build credibility. Watch Q1 earnings May 7 for revenue inflection signal.

NBIS — Nebius | Catalyst

Price: $135.51 | 52w range: $21.45–$168.71 | 20% below 52w high

Narrative: AI21 Labs acquisition talks (growth via M&A). CoreWeave capacity expansion. Aether AI cloud platform launch. PT raised to $175. Stock +600% in a year.

Velocity Score: +6 Hype Score: 6/10 (AI infrastructure demand is real; Yandex spinoff complexity; profitability path unclear) Narrative: Accelerating | Exhaustion signals: 2/5 (600% 1-year move, sentiment consensus) Sentiment Gap: $175 PT vs $135 = ~29% gap to analyst target; below 52w high Verdict: Accelerating but maturing — PT to $175 is the near-term target. M&A integration risk from AI21 Labs.

ONDS — Ondas Holdings | Catalyst

Price: $10.48 | 52w range: $0.73–$15.28 | 31% below 52w high

Narrative: MAJOR catalyst stack. Mistral merger completed $175M (April 24) — new major partnership/supplier trigger. $264M backlog added. $10M Israeli demining order + $50M tender. ONBERG JV Germany/Ukraine. Army drone showcase Modern Day Marine April 28-30 (today). Best month of 2026 (+16%).

Catalyst stack: Merger completion + Israel order + JV launch + Army showcase = 4 catalysts Velocity Score: +8 Hype Score: 7/10 (DoD contracts verifiable; Israeli orders real; drone market structural) Narrative: Accelerating | Exhaustion signals: 0/5 Sentiment Gap: $15.28 52w high vs $10.48 = 46% potential recovery; new backlog structurally changes revenue visibility Supply chain propagation: ONDS Catalyst → check AMPX, ULBI (battery derivatives in drones map) Verdict: Accelerating — Mistral merger transforms ONDS from integrator to prime contractor. Army showcase timing is a near-term narrative catalyst.

AMPX — Amprius | Catalyst

Price: $19.69 | 52w range: $2.10–$22.80 | 14% below 52w high

Narrative: $21M EV order from new Chinese customer. Analyst PT raised to $19.25. Record Q1 revenue, triple-digit YoY growth, positive EBITDA. Q1 earnings May 7. YTD +159.6%. Drone battery moat building.

Catalyst stack: New major customer order + analyst PT upgrade + positive EBITDA first time Velocity Score: +7 Hype Score: 6/10 (P/S 30x vs industry 2.2x — valuation stretched; revenue growth real) Narrative: Accelerating | Exhaustion signals: 2/5 (near 52w high, 159% YTD return) Extended-price rule: 14% from 52w high + fresh customer catalyst = Accelerating (not Exhaustion) Sentiment Gap: At $19.69 near analyst PT $19.25 — consensus caught up; next leg requires Q1 beat Verdict: Accelerating but valuation-stretched — drone/eVTOL TAM expansion story is real but P/S 30x requires execution.

OKLO — Oklo | Catalyst

Price: $69.09 | 52w range: $22.52–$193.84 | 64% below 52w high

Narrative: DOE loans pipeline (5-10 reactors); NVIDIA+Los Alamos nuclear AI factory partnership; 93% pipeline jump; board governance overhaul; HSBC $96 PT. Q1 earnings May 12. SI at ATH 24.1M — massive short interest.

Catalyst stack: NVIDIA partnership + DOE loan pipeline + governance + 93% pipeline growth = 4 catalysts Velocity Score: +7 Hype Score: 7/10 (pre-revenue; 14 GW pipeline but 2027+ deployment; July 4 NRC milestone is near-term) Narrative: Accelerating | Exhaustion signals: 0/5 (64% below 52w high = no exhaustion) Short squeeze risk: 24.1M SI at ATH SI figures inconsistent -- Finviz shows 17.14M, MarketBeat shows 28.6M (Apr 15 reporting date). SI is elevated but exact figure uncertain + catalyst stack = potential short squeeze acceleration [DISPUTED -- OKLO SI figures vary significantly across sources: Finviz 17.14M, MarketBeat 28.6M (Apr 15), main report says 17.14M. The "ATH" characterization may be accurate but the exact share count is unreliable. Directionally correct that SI is elevated.] Supply chain propagation: OKLO Catalyst → LEU (nuclear fuel), NKLR (SMR sector) Verdict: Asymmetric — high SI + growing pipeline + NVIDIA partnership is a compressed spring. July 4 NRC milestone is the near-term test.

NVO — Novo Nordisk | Catalyst

Price: $41.17 | 52w range: $35.12–$81.44 | 50% below 52w high

Narrative: FDA oral Ozempic approval (regulatory win). Pediatric semaglutide label expansion. Foundayo (Lilly oral) weak early uptake = market share preserved. BUT: -5% to -13% 2026 revenue guidance. Goldman/TD Cowen hold/neutral. Mixed signal: regulatory wins vs fundamental deterioration.

Catalyst stack: FDA oral approval + pediatric approval + Lilly competitor weakness Velocity Score: +2 (regulatory wins balanced by revenue deterioration guidance) Hype Score: 6/10 (real products, real approvals, but guidance structurally weak) Narrative: Stabilizing | Exhaustion signals: 1/5 Sentiment Gap: 50% below 52w high; $65 consensus PT vs $41 = massive gap — but the bear case (pricing pressure, LOE risk, guidance cut) explains it Verdict: Stabilizing — oral Ozempic and pediatric wins are positive but don't overcome the -5% to -13% growth guide. Watch for evidence of volume recovery before re-rating.

MU — Micron | Catalyst

Price: $504.29 | 52w high: $531.36 | Within 5% of 52w high

Narrative: HBM 100% sold out 2026, non-cancellable contracts, pricing floors. New LT agreements with hyperscalers. UBS $535 PT; Lynx $825; Keybanc $600 OW. 52w high $506.99 hit April 26. Stock +68% YTD. Extended-price + HBM catalyst = Accelerating.

Catalyst stack: HBM sellout confirmed + analyst PT increases (multiple) + new LT agreements Velocity Score: +9 Hype Score: 8/10 (contracts verifiable, sell-through confirmed, pricing floors real) Narrative: Accelerating | Exhaustion signals: 3/5 (near 52w high, analyst consensus fully upgraded, 68% YTD run, insider selling flagged) Exhaustion warning fires — 3+ signals: near ATH, all analysts upgraded, large YTD move Sentiment Gap: $531 52w high vs $504 — limited gap to 52w high. Lynx $825 implies 63% upside; UBS $535 is near-term Verdict: Accelerating but 3 exhaustion signals fire. The structural thesis (HBM sellout) is durable, but entry here has limited short-term asymmetry vs earlier entries. Watch for consolidation.

AMKR — Amkor | Catalyst

Price: $71.36 | 52w high: $79.23 | Within 10% of 52w high

Narrative: Record Q1 2026 — revenue +27% YoY, EPS $0.33 vs $0.22 est (+50% beat). AI packaging segment tripling YoY. Communications +42%. $2.5-3.0B capex. Extended-price + earnings beat = Accelerating.

Catalyst stack: Earnings beat + record revenue + AI packaging triple + buyback Velocity Score: +8 Hype Score: 8/10 (hard numbers, record quarter, CoWoS overflow confirmed) Narrative: Accelerating | Exhaustion signals: 1/5 (near highs) Sentiment Gap: $79.23 52w high vs $71.36 = ~11% to prior high; Q2 guide of $1.75-1.85B is the next catalyst Supply chain propagation: AMKR Catalyst → confirms gpu_ai_compute thesis → NVDA, MU derivative signal reinforced Verdict: Accelerating — strongest earnings beat in the packaging cluster. Buyback + record quarter + tripling AI packaging is a clean catalyst stack.

MP — MP Materials | Catalyst

Price: $61.70 | 52w range: $18.64–$100.25 | 38% below 52w high

Narrative: Apple $500M magnet deal in production. DoD $110/kg NdPr floor. Sulfuric acid ban T-2 (upstream tailwind for rare earth leaching constraint on China). Heavy rare earth separation facility targeting mid-2026. Wedbush $90 PT. NdFeB magnets for GM ramping.

Catalyst stack: Apple magnet deal + DoD pricing floor + China sulfuric acid ban + GM magnet ramp = 4 catalysts Velocity Score: +8 Hype Score: 8/10 (Apple deal confirmed, DoD contract real, sulfuric acid ban is policy fact) Narrative: Accelerating | Exhaustion signals: 0/5 Sentiment Gap: Wedbush $90 vs $61.70 = 46% upside; 38% below 52w high Supply chain propagation: MP Catalyst → evs_electrification (AMPX, QS) + robotics_automation (NOVT actuators need NdFeB magnets) Verdict: Asymmetric — onshoring story + DoD floor + China supply shock convergence. Mid-2026 heavy RE separation = next structural catalyst.

LITE — Lumentum | Catalyst

Price: $791.37 | 52w range: $56.80–$960.00 | 18% below 52w high

Narrative: $2B NVDA lock-in, OCI Alliance, OFC 2026 AI optical scale-up demo, sold out through 2027. Seeking Alpha "buying after 1300% run" = social sentiment signal. Stock +150% 90d.

Catalyst stack: NVDA $2B lock-in + OFC breakthrough demo + OCI Alliance Velocity Score: +7 Hype Score: 7/10 (NVDA deal real; 1300% run creates exhaustion risk; backlog real but already priced) Narrative: Accelerating | Exhaustion signals: 3/5 (1300% YTD run, social amplification excessive, consensus bullish, near all-time range, Seeking Alpha "buy after 1300%" = late-cycle signal) Exhaustion warning: 3 signals. POET -47% is a single-name event (confidentiality breach) but tests SiPh sector confidence. LITE has no confidentiality issues — POET contagion is noise for LITE fundamentals. POET -47% impact: POET crash does NOT invalidate LITE thesis. POET had company-specific failure (CFO breach). LITE's NVDA partnership is intact. The TSEM -7.3% sympathy sell yesterday is a potential LITE re-entry window. Verdict: Accelerating but 3 exhaustion signals — long-term thesis intact, near-term entry risk elevated. POET-induced pullback = opportunity to add if occurs.

COHR — Coherent | Catalyst

Price: $303.97 | 52w range: $61.05–$364.80 | 17% below 52w high

Narrative: OFC 2026 6.4T CPO demo + next-gen pluggable. NVDA Spectrum-X named collaborator. PT raised to $275 Buy (Stifel). Earnings May 6. POET -47% = validation (COHR's NVDA partnership is intact). POET crash tests whether SiPh sector has idiosyncratic vs systematic risk — COHR answer: idiosyncratic.

Catalyst stack: NVDA partnership + OFC CPO demo + S&P 500 inclusion (prior) + earnings upcoming Velocity Score: +7 Hype Score: 8/10 (25% optical market share, NVDA named partner, FY25 revenue +23%) Narrative: Accelerating | Exhaustion signals: 1/5 POET divergence: POET crash = sentiment test for COHR. COHR held better than expected Apr 28 (sympathy sell was limited). This divergence is bullish for COHR — market distinguishing company quality. Sentiment Gap: $364.80 52w high vs $303.97 = ~20% to prior high; Stifel $275 is below current price — PT lagging Verdict: Accelerating — best risk/reward in SiPh cluster post-POET. No confidentiality risk, NVDA partnership intact, earnings May 6 is next catalyst.

AAOI — Applied Optoelectronics | Catalyst

Price: $137.26 | 52w range: $11.86–$173.41 | 21% below 52w high

Narrative: $71M hyperscale 800G order (April 2) — major customer order doubled. Stock up 44.93% 7d. 1-year return ~965%. Analysts average PT $66.80 vs $137.26 price — analysts 51% below current price. "May test" flagged (earnings May 7).

Catalyst stack: Major hyperscale order + $1B 2026 revenue target on track Velocity Score: +5 Hype Score: 5/10 — PRIMARY CONCERN: analysts at $66.80 vs stock at $137. 51% analyst-to-price gap is the most extreme exhaustion signal in the entire watchlist. Narrative: Accelerating but EXHAUSTION WARNING | Exhaustion signals: 4/5

• Stock up 44.93% in 7 days on a $71M order
• 1-year return ~965% (extreme move)
• Analyst consensus $66.80 vs $137 price — market massively ahead of analysts
• Stock at 3.60x 200MA
• Options market pricing significant move for May 7 earnings Sentiment Gap: OVEREXTENDED — price is running far ahead of fundamentals. Analyst consensus implies 51% downside from current levels. Verdict: Exhaustion imminent — 4/5 exhaustion signals. The hyperscale orders are real, but price has run so far beyond analyst targets that the asymmetry has reversed. Earnings May 7 is binary; a miss would be severe.

RVMD — Revolution Medicines | Catalyst

Price: $144.83 | 52w range: $34.00–$155.70 | Within 7% of 52w high

Narrative: ASCO plenary session confirmed for Phase 3 RASolute 302 (May 31) — pivotal data already known (13.2m OS vs 6.7m, HR 0.40). Phase 1/2 first-line data at AACR April 21. RASolute 303 Phase 3 started. NDA filing expected. Extended-price + ASCO plenary = Accelerating.

Catalyst stack: ASCO plenary confirmed + Phase 1/2 data + Phase 3 dosing started + NDA expected Velocity Score: +9 Hype Score: 9/10 (peer-reviewed Phase 3 data, ASCO plenary = highest oncology validation, primary endpoint clear) Narrative: Accelerating | Exhaustion signals: 2/5 (near 52w high, consensus bullish) Sentiment Gap: Stock within 7% of 52w high; ASCO plenary May 31 = next major repricing event. NDA filing timing = multi-year catalyst Supply chain propagation: RVMD Catalyst → NVCR (both PDAC oncology — market may compare/contrast) Verdict: Asymmetric — ASCO plenary is the highest validation stage for oncology. Phase 3 data already proven; plenary is about partner/acquirer attention. NDA filing = potential partnership/M&A catalyst.

TSEM — Tower Semiconductor | Catalyst

Price: $193.55 | 52w range: $34.73–$228.73 | 15% below 52w high

Narrative: Axiro US SiGe radar chip partnership (April 27) — new major partnership trigger. POET -47% caused sympathy sell (-7.3% April 28). But TSEM's thesis is fundamentally different from POET: TSEM is production-grade SiPh foundry, POET was a component integrator with a confidentiality problem. Q1 earnings May 13.

Catalyst stack: Axiro US partnership + 70% SiPh revenue YoY + NVIDIA partnership + POET crash = opportunity Velocity Score: +5 (post-POET sympathy sell depressed) Hype Score: 8/10 (70% capacity reserved through 2028, NVIDIA named partner, SiGe radar defense pivot) Narrative: Accelerating — POET crash is idiosyncratic; TSEM's foundry role is irreplaceable Sentiment Gap: $228.73 52w high vs $193.55 = ~18% to prior high; POET sympathy sell created artificial discount Verdict: Inflection — POET crash created a sentiment gap that doesn't match the fundamental reality for TSEM. The sympathy sell is the entry signal, not an exit. May 13 earnings = next catalyst.

AEHR — Aehr Test Systems | Catalyst

Price: $82.43 | 52w range: $8.02–$102.48 | 20% below 52w high

Narrative: New major SiPh customer (March 31). $41M hyperscale AI order (April 16 +18.96%). FOX-XP systems shipping Q4 FY26 (May 29). Only SiPh/AI-ASIC wafer burn-in vendor — structural monopoly. POET -47% does not affect AEHR (AEHR tests SiPh wafers, not integration).

Catalyst stack: New customer + $41M order + systems shipping this quarter + no POET exposure Velocity Score: +8 Hype Score: 8/10 (monopoly position, verifiable orders, shipment timeline confirmed) Narrative: Accelerating | Exhaustion signals: 1/5 (2.94x 200MA) POET impact: None — AEHR's customers are testing SiPh at wafer level regardless of POET. The bottleneck AEHR addresses is upstream of where POET failed. Verdict: Accelerating — structural monopoly on SiPh test + hyperscale order + Q4 shipment timeline. POET crash creates noise but no fundamental impact.

CRDO — Credo Technology | Catalyst

Price: $165.92 | 52w range: $40.17–$213.80 | 22% below 52w high

Narrative: $750M DustPhotonics acquisition (April 13) — new major partnership/acquisition trigger. Jefferies initiation Buy $175 PT. Vertically integrated 400G-3.2T. $500M+ optical revenue target FY2027.

Catalyst stack: DustPhotonics acquisition + Jefferies initiation + vertical integration completion Velocity Score: +7 Hype Score: 7/10 (acquisition announced, Jefferies credible, but integration risk real) Narrative: Accelerating | Exhaustion signals: 1/5 Sentiment Gap: Jefferies $175 vs $165.92 = 6% to initial target; 22% to 52w high; more upside if FY2027 $500M optical revenue materializes Verdict: Accelerating — DustPhotonics integration makes CRDO vertically integrated in SiPh. Best risk/reward vs AAOI at this point given 1.22x 200MA vs AAOI's extreme multiple.

AXTI — AXT Inc | Catalyst

Price: $68.71 | 52w high: $90.10 | Within 24% of 52w high (not extended)

Narrative: $550M public offering + $82.5M over-allotment = $632.5M raised. Northland PT doubled $45→$90. Q1 earnings tomorrow April 30. CEO sold $6.9M in shares. InP monopoly story confirmed. Motley Fool "up 6,000% in a year."

Catalyst stack: Massive capital raise + Northland PT doubling + Q1 earnings tomorrow Velocity Score: +6 Hype Score: 6/10 — CEO selling $6.9M is a notable bearish insider signal; offering dilution creates near-term headwind; 6,000% YTD move is extreme Narrative: Accelerating BUT high risk | Exhaustion signals: 4/5

• CEO selling $6.9M
• $550M dilutive offering after massive run
• Average analyst PT $22.80 vs $68.71 (67% analyst downside implied)
• 6,000% YTD return — most extreme in watchlist
• Consensus analyst "Hold" vs Northland outlier $90 PT Sentiment Gap: OVEREXTENDED — like AAOI, the price has massively outrun analyst consensus. The structural InP bottleneck thesis is sound but the position is dangerous near-term. Verdict: Exhaustion warning — 4/5 signals. Tomorrow's Q1 earnings (preliminary rev $26-28M vs $632M raise) = high volatility. CEO selling into the offering is a clear caution signal.

LEU — Centrus Energy | Catalyst

Price: $205.59 | 52w range: $66.38–$464.25 | 56% below 52w high

Narrative: Piketon expansion — Geiger Brothers selected for multi-billion centrifuge deployment (thousands of AC100M units). +12MT HALEU/yr output targeted. $2.3B commercial LEU backlog. B. Riley Buy (PT $315→$295 trim). DOE loan for first 5-10 reactors benefits fuel chain.

Catalyst stack: Piketon expansion partner + HALEU output target + DOE tailwind + Oklo JV Velocity Score: +7 Hype Score: 8/10 (DOE award verifiable, Oklo JV confirmed, only HALEU enricher in US) Narrative: Accelerating | Exhaustion signals: 0/5 Sentiment Gap: B. Riley $295 vs $205 = 44% upside; 56% below 52w high; significant recovery potential Supply chain propagation: LEU = nuclear_energy chain derivative — OKLO Catalyst directly confirms LEU thesis Verdict: Accelerating — HALEU bottleneck moat + expanding production + DOE loan tailwind. Price 56% below highs gives significant upside vs risk.

BTU — Peabody Energy | Catalyst

Price: $26.90 | 52w range: $12.19–$41.14 | 35% below 52w high

Narrative: Hormuz Day 16 (Brent $111+ Correction: Brent $114.64) = coal demand displacement. Australian mines capacity-constrained (running full). Asian customers "pleading" for more shipments. Centurion mine ramping. Stock +8.3% 7d. [PARTIALLY VERIFIED -- Brent price is $114.64 per TradingEconomics, not "$111+". The sentiment scan was drafted before the main report's price update.]

Velocity Score: +5 (Hormuz-driven, not company-specific) Hype Score: 6/10 (Hormuz disruption is real; coal thesis is geopolitical, not structural) Narrative: Accelerating | Exhaustion signals: 1/5 Sentiment Gap: $41.14 52w high vs $26.90 = 53% potential recovery; Hormuz duration is the key variable Verdict: Accelerating (Hormuz-contingent) — thesis requires Hormuz to remain disrupted. At 35% below highs, significant upside if disruption extends. Risk: de-escalation = rapid unwinding.

NVCR — NovoCure | Catalyst

Price: $12.12 | 52w range: $9.82–$20.06 | 40% below 52w high

Narrative: Earnings tomorrow April 30 (before open) — binary event. PANOVA-4 data confirmed (DCR 74.4% vs 48% historical). ASCO May 31 pending (overlap with RVMD PDAC data — market may compare). EPS expected -$0.49.

Catalyst stack: PANOVA-4 data + Q1 earnings tomorrow + ASCO presentations Velocity Score: +5 (data positive but execution risk on revenue ramp) Hype Score: 7/10 (Phase 2 data real, but Phase 2 vs Phase 3 distinction matters) Narrative: Accelerating-to-Inflection | Exhaustion signals: 0/5 RVMD comparison: NVCR has Phase 2 PANOVA-4 data; RVMD has Phase 3 confirmed. Market may discount NVCR's data vs RVMD's proven efficacy in same indication. This creates potential valuation gap. Sentiment Gap: $20.06 52w high vs $12.12 = 65% potential recovery; $1.4B cap for a genuine PDAC efficacy signal is compelling Verdict: Accelerating — earnings tomorrow is the near-term binary. If revenue holds and guidance is maintained, the PANOVA-4 data narrative has room to run. ASCO May 31 = second catalyst.

NOVT — Novanta | Catalyst

Price: $128.98 | 52w range: $98.27–$149.95 | 14% below 52w high

Narrative: Earnings May 11 (not April 30 — confirmed). 2025 bookings +25%, book-to-bill 1.11x. $50M warehouse deal. NVIDIA Halos robotics lab member. Actuators = 30-50% humanoid robot BOM. Not yet widely tagged as humanoid play.

Velocity Score: +6 Hype Score: 7/10 (real revenue, real bookings growth, NVIDIA Halos is new partnership signal) Narrative: Accelerating | Exhaustion signals: 1/5 (within 14% of highs) Sentiment Gap: $149.95 52w high vs $128.98 = 16% to prior high; if humanoid narrative attaches, significant re-rate possible Supply chain: NOVT → robotics_automation map: actuators bottleneck Verdict: Accelerating — robotics actuator bottleneck story is building. May 11 earnings = near-term catalyst. Humanoid narrative gap is the asymmetric opportunity.

INFQ — Infleqtion | Catalyst

Price: $12.62 | 52w range: $8.52–$21.28 | 41% below 52w high

Narrative: $1M US Navy QuIRC contract. Monarch Quantum funding (April 24). BTIG Buy $22 PT. DARPA $2M contract. Both analysts are Strong Buy.

Velocity Score: +5 Hype Score: 5/10 (small contracts, early revenue, but defense contracts are verifiable) Narrative: Accelerating-to-Stabilizing | Exhaustion signals: 0/5 Catalyst Timeline: No binary events in near term; thesis is long-duration Verdict: Stabilizing — government contract cadence is building but small ($1M, $2M). Thesis requires larger contract wins to catalyze next leg. BTIG $22 PT vs $12.62 implies 74% upside.

TSLA — Tesla | Catalyst

Price: $376.02 | 52w range: $270.78–$498.83 | 25% below 52w high

Narrative: Q1 earnings showed Robotaxi paid miles doubled QoQ but revenue disappointment. $25B capex guide. Optimus production late July/Aug target. FSD unsupervised potentially late 2026. 4M vehicles need HW upgrades. Goldman $375 Neutral.

Velocity Score: +3 (mixed signals; capex concern vs robotaxi progress) Hype Score: 6/10 (optimus/robotaxi are real but timeline risk high) Narrative: Stabilizing | Exhaustion signals: 1/5 Verdict: Stabilizing — catalysts exist (Optimus, Robotaxi) but timeline execution risk is high and near-term revenue is disappointing. Goldman $375 Neutral = fair value at current price.

NVO — Novo Nordisk | Catalyst summary

See above — Stabilizing. Regulatory wins vs revenue guide deterioration.

Phase 3.7: Supply Chain Sentiment Propagation

GPU/AI Compute → Downstream

Primary signal: NVDA near ATH + AMKR record beat + GOOGL/MSFT/AMZN earnings tonight

ONDS Drones → Drone Supply Chain

Primary signal: ONDS Mistral merger + Israeli orders

Highest alpha window: ULBI — ONDS merger adds DoD drone prime capacity; ULBI defense battery exposure not yet priced as derivative

Nuclear → Fuel/Enrichment

Primary signal: OKLO NVIDIA partnership + DOE loan pipeline + LEU Piketon expansion

Propagation opportunity: NKLR — SMR DOE loan pipeline (5-10 reactors) is sector tailwind; NKLR price ($6.34) hasn't moved with OKLO

Rare Earth → Robotics/EV

Primary signal: MP Materials Apple deal + DoD floor + sulfuric acid ban T-2

Oncology → Sector Comparison

Primary signal: RVMD Phase 3 confirmed + ASCO plenary May 31

Exhaustion Warnings (3+ signals)

AAOI — 4/5 Exhaustion Signals

• 44.93% 7-day return on a single $71M order
• ~965% 1-year return (most extreme move in watchlist)
• Analyst avg PT $66.80 vs $137.26 price (analysts 51% below market)
• Stock at 3.60x 200MA Assessment: Easy money likely done. Earnings May 7 = binary risk. PT disconnect vs price is the primary warning.

AXTI — 4/5 Exhaustion Signals

• ~6,000% YTD return
• CEO selling $6.9M shares into offering
• Analyst avg PT $22.80 vs $68.71 (analysts 67% below market)
• $550M dilutive offering after massive run Assessment: Structural thesis intact (InP monopoly), but the offering price ($64.25) is now support. Q1 earnings tomorrow = binary event. Northland $90 PT is outlier vs consensus.

MU — 3/5 Exhaustion Signals

• Near 52w high (ATH $506.99 hit April 26)
• 68% YTD return
• All major analysts already upgraded Assessment: HBM thesis durable; short-term entry risk elevated. Wait for consolidation.

LITE — 3/5 Exhaustion Signals

• 1300% 12-month return
• Social amplification (Seeking Alpha "buy after 1300%" = late-cycle retail signal)
• Consensus uniformly bullish Assessment: Structural thesis (NVDA lock-in, OCI Alliance) is real but the easy move is done. POET-induced pullback = better entry.

Noise Tickers

Quiet Tickers

Inflection Points

HIMS — Inflection

Before: Lawsuit target of Novo Nordisk, compounding ban risk, legal overhang. After: Partnership with Novo Nordisk → Wegovy on platform, JPMorgan Overweight initiation, menopause TAM expansion, peptide optionality. Gap: 60% below 52w high. JPM $35 PT = +25% from current. Amazon entry = near-term headwind but doesn't invalidate the platform story.

TSEM — Inflection

Before: POET crash caused -7.3% sympathy sell April 28 — market pricing TSEM as POET-adjacent. After: TSEM has no confidentiality issues, NVIDIA partnership intact, Axiro US radar chip partnership announced April 27. The POET failure is company-specific (CFO breach); TSEM is the foundry making 70%+ of 1.6T PICs. Gap: 15% to 52w high; POET sympathy discount is artificial.

OKLO — Asymmetric

NVIDIA+Los Alamos nuclear AI factory, DOE loan pipeline, 24.1M SI at ATH = compressed spring. ATH short interest + growing pipeline = explosive short squeeze potential on July 4 NRC milestone.

Data Quality Notes

• NFLX earnings classified Noise (Q1 was April 16, outside 7-day window)
• NOVT earnings corrected to May 11 (not April 30 as originally stated in brief)
• POET -47% (April 28) = company-specific (CFO confidentiality breach); not SiPh sector contagion
• AXTI earnings confirmed April 30 (preliminary rev $26-28M already disclosed)
• TSEM down 7.3% April 28 = POET sympathy, not fundamental
• BTU price: $26.90 (+8.3% 7d) — Hormuz tail continues

Companion file saved: research/reports/2026-04-29/sentiment-scan.md